Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib + Chemotherapy in CDK4/6-Dependent Solid Tumors
NCT07490236Phase 1Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Jan 2023
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of trilaciclib in solid tumor (2 arms), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Incidence of grade 3-4 myelosuppression at 4 weeks. Started Jan 2023; status: recruiting.
02
Drugs
trilaciclib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07490236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07490236.